Cost-effectiveness analysis of UGT1A1 genetic testing to inform antiretroviral prescribing in HIV disease.

Schackman BR, Haas DW, Becker JE, Berkowitz BK, Sax PE, Daar ES, Ribaudo HJ, Freedberg KA
Antivir Ther. 2013 18 (3): 399-408

PMID: 23264445 · PMCID: PMC3744167 · DOI:10.3851/IMP2500

MeSH Terms (12)

Adult Antiretroviral Therapy, Highly Active Cost-Benefit Analysis Female Genetic Testing Genotype Glucuronosyltransferase HIV Infections Humans Male Middle Aged Quality-Adjusted Life Years

Connections (1)

This publication is referenced by other Labnodes entities: